Abstract CT181: A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors

医学 耐受性 放射免疫疗法 内科学 肺癌 药代动力学 药理学 临床研究阶段 恶心 最大耐受剂量 治疗指标 胃肠病学 抗体 不利影响 化疗 药品 单克隆抗体 免疫学
作者
Jie Wang,Lin Wu,Zhengbo Song,Xingya Li,Caigang Liu,Tianshu Liu,Yiwen Wu,Ze Zhang,Shuni Wang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): CT181-CT181 被引量:10
标识
DOI:10.1158/1538-7445.am2023-ct181
摘要

Abstract Background: SHR-A1921 is a novel ADC composed of a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) IgG1 monoclonal antibody attached to a DNA topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Herein, we present the preliminary clinical results of the FIH study of SHR-A1921. Methods: This is a multi-center, open-label, phase 1 trial (Clinicaltrials.gov, NCT05154604) consisted of dose-escalation, dose-expansion and efficacy-expansion phases. Patients with advanced solid tumors who had failed standard therapy were enrolled. In the dose-escalation phase, SHR-A1921 was planned to be administered from 1.5 mg/kg to 12.0 mg/kg (Q3W, iv) in an i3+3 design, with accelerated titration used for the starting dose; in the dose-expansion phase, additional patients (up to 20-30 per dose level) were enrolled to 2-3 selected tolerable dose levels. The primary objectives were to evaluate the safety and tolerability of SHR-A1921 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose. Results: As of Oct 21. 2022, 38 enrolled patients were included for analysis: 18 enrolled during dose-escalation (1.5 mg/kg, n=1; 3.0 mg/kg, n=4; 4.0 mg/kg, n=8; 6.0 mg/kg, n=5) and 20 during dose-expansion (3.0 mg/kg). 71.1% (27/38) were driver gene-negative non-small cell lung cancer (NSCLC) patients who had previously received platinum-based chemotherapy and anti-PD-(L)1 antibody. 4 patients reported dose-limiting toxicities, with all being grade 3 stomatitis (6.0 mg/kg, n=3; 4.0 mg/kg, n=1). The MTD was established as 4.0 mg/kg. Across all dose cohorts, the most common treatment-related adverse events (TRAEs; ≥30%) were nausea (71.1%), stomatitis (65.8%), anemia (42.1%), vomiting, decreased appetite, decreased weight, and rash (36.8% each). Grade ≥3 TRAEs occurred in 12 patients (31.6%); of these, the most common was stomatitis (n=7, 18.4%), and all other events were reported in ≤2 patients. No patients discontinued study treatment due to TRAEs. As of cut-off date, 10 patients (NSCLC, n=5; triple-negative breast cancer, n=2; ampullary cancer, n=2; ovarian cancer, n=1) had partial response: 4 confirmed and 6 requiring further confirmation. The objective response rate was 33.3% (10/30; 95% CI 17.3-52.8) and disease control rate was 80.0% (24/30; 95% CI 61.4-92.3) in evaluable patients. Conclusion: SHR-A1921 showed a manageable safety profile and promising anti-tumor activity in patients with pretreated advanced cancer. The trial is ongoing to assess SHR-A1921 at different dosing frequency and the efficacy in selected cancer types. Citation Format: Jie Wang, Lin Wu, Zhengbo Song, Xingya Li, Caigang Liu, Tianshu Liu, Yiwen Wu, Ze Zhang, Shuni Wang. A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT181.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
哈47发布了新的文献求助10
1秒前
彩虹桥发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
anna1992发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
赘婿的应助被jingjing采纳,获得10
2秒前
3秒前
Unless发布了新的文献求助10
3秒前
SciGPT的应助被风趣青槐采纳,获得10
3秒前
李爱国的应助被WATQ采纳,获得10
3秒前
郑睿涛发布了新的文献求助10
4秒前
Laoma发布了新的文献求助10
4秒前
神宝嘎li完成签到,获得积分0
5秒前
yao发布了新的文献求助10
5秒前
小旋风完成签到,获得积分10
5秒前
Ma发布了新的文献求助10
5秒前
DuMilk完成签到,获得积分10
5秒前
有魅力的雨梅完成签到,获得积分10
6秒前
小王发布了新的文献求助10
6秒前
鸭梨发布了新的文献求助10
6秒前
yhuyfuhk完成签到 ,获得积分10
6秒前
呆萌发布了新的文献求助10
6秒前
田様的应助被Mxr采纳,获得10
7秒前
7秒前
董亦菲发布了新的文献求助10
7秒前
猫好好发布了新的文献求助10
7秒前
7秒前
7秒前
8秒前
Jevon完成签到 ,获得积分10
8秒前
8秒前
qiu发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046